Screener
Halozyme Therapeutics HALO Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssets.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Prepaid manufacturing expenses | $86,872 | $71,925 |
| Other prepaid expenses | 44,768 | 14,563 |
| Long-term inventories | 14,839 | 20,768 |
| Other assets | 17,670 | 10,934 |
| Total prepaid expenses and other assets | 164,149 | 118,190 |
| Less long-term portion | (55,090) | (53,551) |
| Total prepaid expenses and other assets, current | $109,059 | $64,639 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's other non-current assets?
- Halozyme Therapeutics (HALO) reported other non-current assets of $17.67M in Q2 2026.
- How has Halozyme Therapeutics's other non-current assets changed year-over-year?
- Halozyme Therapeutics's other non-current assets decreased by 17.4% year-over-year, from $21.38M to $17.67M.
- What is the long-term trend for Halozyme Therapeutics's other non-current assets?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's other non-current assets has grown at a 18.0% compound annual growth rate (CAGR), from $4.78M to $10.93M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Halozyme Therapeutics's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude